The FDA warned that proton-pump inhibitors (PPIs) can trigger the development of Clostridium difficile-associated diarrhea (CDAD). The agency is working with manufacturers of the stomach acid drugs to include information in the labels about the increased risk.
US regulators examined the Adverse Event Reporting System for reports of CDAD associated with the drugs, as well as 28 observational studies. While the strength of the association varied widely between studies, the agency concluded that "the weight of evidence suggests a positive association between the use of PPIs and C. difficile infection and disease." Specifically, the FDA said that studies showed that using the drugs may raise the risk of C. difficile infection or disease, including CDAD, by between 1.4 and 2.75 times.
The FDA also said it is reviewing whether histamine H2 receptor blockers can also trigger the illness
Especializado en DIABETES, EDUCACIÓN DIABETOLÓGICA y MEDICINA INTERNA Aquí encontrarás temas relacionados a la medicina del adulto y otros temas interesantes
domingo, 19 de febrero de 2012
sábado, 11 de febrero de 2012
viernes, 3 de febrero de 2012
Y yo que no creìa en absolutamente ninguna terapia alternativa...
Muscle Massage Rubs Out Inflammation
By Charles Bankhead, Staff Writer, MedPage Today
Published: February 02, 2012
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
Heavily stressed muscles responded to massage therapy with a variety of biologic changes associated with reduced inflammation, analysis of tissue specimens showed.
Serial quadriceps-muscle biopsies showed reduced production of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin-6 (IL-6) following massage treatment of exercise-induced muscle damage.
Massage also was associated with activation of signaling pathways involved in stretch response and mitochondrial biogenesis, as reported online in Science Translational Medicine.
"Our findings suggest that the perceived positive effects of massage are a result of an attenuated production of inflammatory cytokines, which may reduce pain by the same mechanism as conventional anti-inflammatory drugs such as NSAIDs," according to Mark A. Tarnopolsky, MD, PhD, of McMaster University in Hamilton, Ontario, and colleagues.
"These results elucidate the biological effects of massage in skeletal muscle and provide evidence that manipulative therapies may be justifiable in medical practice."
The role of complementary and alternative medicine, including massage therapy, has expanded greatly as an adjunct to conventional medical practice. For many of the techniques, however, there is limited evidence regarding cellular or mechanistic effects to support their clinical use, the authors wrote in their introduction.
Massage therapy has been widely used as an aid to reduce pain and promote recovery of injured muscles. Hypothesized effects of massage have included moderation of inflammation, improved blood flow, and reduced tissue stiffness, all contributing to pain reduction, the authors continued.
The functional benefits of massage have remained unclear and controversial. Experiments in preclinical models have limited applicability because of their failure to mimic human responses. Despite reported long-term benefits of massage in chronic pain and range of motion, the biologic basis has eluded explanation.
To pin down the biologic effects of massage, Tarnopolsky and colleagues recruited 11 healthy male volunteers for a clinical study.
Each participant completed a standardized 15-minute period of intense exercise. Immediately after completing the exercise, participants received 10 minutes of massage for one leg and no treatment for the other leg.
Investigators obtained specimens of participants' quadriceps at rest, immediately after massage, and after a 2.5-hour recovery period.
Using whole-genome microarrays, Tarnopolsky and colleagues examined gene expression associated with massage and then performed targeted reverse transcriptase-polymerase chain reaction studies, analyzed protein signaling, and quantified metabolite production.
As compared with baseline values, muscle tissue from the control leg exhibited changes in expression of 592 genes 30 minutes after exercise and 1,309 genes after the recovery period. Investigators identified five genes that exhibited changes in expression immediately after massage and four genes that differed in expression levels after the recovery period.
The five genes with altered expression immediately after massage included one that was functionally related to actin dynamics. One of the four genes with altered expression after the recovery period was related to nuclear factor kappa-B nuclear trafficking.
"Overall, this profile suggested that massage altered processes related to the cytoskeleton and to inflammation, with the former process being activated early after massage and the latter induced later in recovery," the authors wrote.
To examine muscle damage and activation of mechanical signaling, the investigators assessed focal adhesion kinase (FAK) and extracellular signal-regulated kinase 1/2 (ERK1/2), signaling proteins involved in mechanotransduction in skeletal muscle. Levels of both proteins were elevated immediately after massage, suggesting a role in the transmission of the mechanical stimulus of massage therapy.
Massage had no effect on key regulators of growth signaling and metabolite accumulation, including lactate, glycogen, proglycogen, and macroglycogen.
The investigators also found that massage was associated with increased expression of nuclear peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1-alpha), a mediator of tissue repair and metabolic control, after the recovery period. The observation was in accordance with increased expression of FAK, which controls expression of PGC-1-alpha.
Also after the post-massage recovery period, the authors found increased expression of COX7B and ND1 mRNA -- which are encoded by nuclear and mitochondrial genes and transcriptionally activated by PGC-1-alpha -- "confirming that mitochondrial biogenesis signaling was augmented by massage therapy."
In the immediate post-massage period, pro-inflammatory NF-kappa-B signaling was diminished. After the post-massage recovery period, phosphorylation of heat-shock protein 27 (a marker of cellular stress) was reduced compared with the control situation, as were concentrations of interleukin-6 and tumor necrosis factor-alpha.
The authors had no relevant disclosures.
Primary source: Science Translational Medicine
Source reference:
Crane JD, et al "Massage therapy attenuates inflammatory signaling after exercise-induced muscle damage" Sci Transl Med. 2012; DOI:10.1126/scitranslmed.3002882.
jueves, 2 de febrero de 2012
linagliptin/metformin
FDA clears Eli Lilly, Boehringer Ingelheim's diabetes therapy Jentadueto (Ref: NASDAQ, PR Newswire, FinanzNachrichten, The Wall Street Journal)
January 31st, 2012
By: Matthew Dennis
Tags: Boehringer IngelheimDiabetesFDAGeneral PracticeInternal MedicineJentaduetoLillyMarketing & SalesRegulatory AffairsTradjenta
1
inShare.Email
PrintEli Lilly and Boehringer Ingelheim announced that the FDA approved the combination therapy Jentadueto (linagliptin/metformin) for the treatment of adults with type 2 diabetes. The product combines the DPP-4 inhibitor Tradjenta (linagliptin), which was cleared by the agency last May, with metformin.
Specifically, Jentadueto was authorised by the regulator for use alone or in combination with a sulfonylurea to lower blood sugar in adults with type 2 diabetes. Eli Lilly and Boehringer Ingelheim noted that the approval was based on data from studies in which Tradjenta and metformin were evaluated as separate tablets, with bioequivalence of Jentadueto shown in healthy subjects. The companies said that in clinical trials, Jentadueto demonstrated placebo-corrected reductions in HbA(1c) levels of up to 1.7 percent.
In January 2011, Eli Lilly and Boehringer Ingelheim entered a deal to jointly develop and market several diabetes compounds, including Tradjenta
January 31st, 2012
By: Matthew Dennis
Tags: Boehringer IngelheimDiabetesFDAGeneral PracticeInternal MedicineJentaduetoLillyMarketing & SalesRegulatory AffairsTradjenta
1
inShare.Email
PrintEli Lilly and Boehringer Ingelheim announced that the FDA approved the combination therapy Jentadueto (linagliptin/metformin) for the treatment of adults with type 2 diabetes. The product combines the DPP-4 inhibitor Tradjenta (linagliptin), which was cleared by the agency last May, with metformin.
Specifically, Jentadueto was authorised by the regulator for use alone or in combination with a sulfonylurea to lower blood sugar in adults with type 2 diabetes. Eli Lilly and Boehringer Ingelheim noted that the approval was based on data from studies in which Tradjenta and metformin were evaluated as separate tablets, with bioequivalence of Jentadueto shown in healthy subjects. The companies said that in clinical trials, Jentadueto demonstrated placebo-corrected reductions in HbA(1c) levels of up to 1.7 percent.
In January 2011, Eli Lilly and Boehringer Ingelheim entered a deal to jointly develop and market several diabetes compounds, including Tradjenta